Radioactive Gold: The $8 Billion Bet That Nuclear Medicine Is Biotech's Next Frontier

Curium was formed in 2017 from the merger of IBA Molecular and Mallinckrodt Nuclear Medicine. It's controlled by CapVest, a private equity firm, and it operates a large network of manufacturing sites worldwide. That includes a molybdenum processing plant (molybdenum-99 is the workhorse isotope behind most nuclear medicine scans), multiple SPECT manufacturing facilities, and 44 nuclear pharmacies.

In plain English: Curium owns the factory, the supply chain, and the delivery trucks. Lantheus owns the products that hospitals are ordering. Combining them is like a brewery buying the most popular bar in town.

Radiopharmaceuticals are fundamentally different from regular drugs. These products are radioactive, which means they decay. Some have half-lives measured in hours. You can't stockpile them in a warehouse. You need to manufacture them close to where they'll be used, and you need to get them there fast. That makes manufacturing infrastructure incredibly valuable, and incredibly hard to replicate.

Why Nuclear Medicine Became the Hottest Date in Oncology

The real fuel behind this deal is a broader revolution in cancer treatment called radioligand therapy (RLT). The concept is beautifully simple: attach a radioactive atom to a molecule that seeks out cancer cells, inject it, and let it deliver targeted radiation directly to the tumor. Same targeting principle as Pylarify's diagnostics, but instead of just finding cancer, you're killing it.

Novartis proved the concept could work at massive commercial scale with Pluvicto, a radioligand therapy for metastatic prostate cancer. Pluvicto generated $1.39 billion globally in 2024 and captured over half the radioligand therapy market's revenue in 2025. When the FDA expanded its approval in 2026 to cover earlier-stage patients, the addressable market got even bigger.

The radioligand therapy market is growing rapidly, with forecasts projecting it could reach well into the tens of billions of dollars by 2035. The direction is unmistakable: up and to the right.

This is the context that makes Curium's move logical. Pluvicto showed the world that radioligand therapies work. Now every major pharma company wants in. But you can't make these drugs without isotopes, cyclotrons, specialized manufacturing, and regulatory-approved facilities. Curium already has all of that. Add Lantheus's commercial products and clinical relationships, and you've got a company that can play on both sides of the theranostics coin: diagnosis and treatment.

Show Me the Money (and the Fine Print)

Let's talk deal structure, because the details matter.

Lantheus shareholders will receive $102.50 per share in cash at closing. On top of that, they get contingent value rights (CVRs) worth up to $12.00 per share. CVRs are essentially IOUs: you only get paid if the company hits certain performance milestones. In this case, those milestones are tied to sales targets for Lantheus's prostate diagnostics, neurology diagnostics, and DEFINITY businesses through 2030.

The milestones aren't trivial. Prostate diagnostics would need to hit between $950 million and $1.75 billion in fiscal 2030 sales. Neurology diagnostics targets are set at $300 million or $350 million in certain fiscal years. DEFINITY would need to clear $400 million in fiscal 2030. These are stretch goals, not layups.

At maximum value, the deal works out to $114.50 per share, or roughly $8 billion total. The total maximum consideration of $114.50 per share represented about a 21% premium to Lantheus's unaffected closing price of $94.47 on May 21, 2026, before takeover speculation started swirling. Compared to the stock's 60-day volume-weighted average price, the premium was 38%.

For context on the stock's wild ride: Lantheus ended 2024 at $89.46 after a 44% annual gain. Then it cratered, closing 2025 at just $55.50, a nearly 38% decline. By the time the deal leaked, shares had recovered to the high $90s. The acquisition price lands well below Lantheus's all-time high of $123.62, hit in July 2024.

Wall Street's Verdict: Fair, Not Generous

Analysts were measured in their enthusiasm. The consensus? Lantheus shareholders are getting a reasonable exit, not a windfall.

B. Riley's Yuan Zhi called the $102.50 upfront price "fair" but "not generous," noting it was below where many investors had positioned themselves. William Blair's Andy Hsieh was more upbeat, calling it an "excellent outcome" and arguing that operational headwinds and a thin field of potential bidders made a higher offer unlikely.

On the regulatory front, Jones Trading's Justin Walsh flagged that the merger could face "relatively high regulatory scrutiny" since both companies are significant players in diagnostic radiopharmaceuticals. When you're combining two of the biggest suppliers in a specialized market, antitrust reviewers tend to take a closer look.

Both TD Cowen and B. Riley downgraded Lantheus stock after the announcement, essentially telling investors there wasn't much upside left beyond the deal price. The mood was hold-and-wait, not pop-the-champagne.

The Bigger Picture: A New Pharma Arms Race

Zoom out, and this deal is a signal flare. The radiopharmaceutical space is entering its consolidation phase, and the logic is straightforward.

Making radioactive drugs requires specialized infrastructure that takes years and billions of dollars to build. Isotope supply chains are fragile and geographically constrained. Regulatory barriers are high. All of this creates a natural moat for companies that already have the manufacturing footprint, and a compelling reason to acquire rather than build from scratch.

Novartis proved the commercial thesis with Pluvicto. Now the race is on to lock up the next wave of radioligand therapies, the manufacturing capacity to produce them, and the diagnostic tools to identify which patients should receive them. Curium's acquisition of Lantheus is a bet that owning the full stack (from isotope production to patient diagnosis to drug delivery) will be the winning strategy.

The deal still needs Lantheus shareholder approval and regulatory clearance, so nothing is final. But if it closes, the combined company will have a vast manufacturing network, a billion-dollar diagnostic franchise, and a front-row seat to one of oncology's most promising new treatment categories.

Five years ago, nuclear medicine felt like a relic. Now it's an $8 billion prize. The atoms are small, but the ambitions are enormous.